Acutus Medical
10840 Thornmint Road
San Diego
California
United States
Tel: 858-673-1621
Fax: 858-673-2274
Website: http://acutusmedical.com/
115 articles about Acutus Medical
-
Acutus Medical Appoints Niamh Pellegrini to Board of Directors
8/12/2021
Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced the appointment of Niamh Pellegrini to the Company's Board of Directors, effective August 10, 2021.
-
AcQMap 8, Acutus Medical’s Innovative Suite of Software Upgrades, Receives FDA Clearance and CE MarkEnhanced Software Automatically Identifies Regions of Interest During the Treatment of Complex Atrial Arrhythmias
8/11/2021
Acutus Medical, Inc. (Nasdaq: AFIB) (“Acutus”), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced its innovative suite of software upgrades, known collectively as AcQMap 8, has received FDA clearance and been awarded CE Mark.
-
Acutus Medical to Participate at the 6th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference
8/3/2021
Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will attend investor meetings at the 6th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference
-
Acutus Medical to Announce Second Quarter 2021 Financial Results
7/29/2021
Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced it will release its financial results for the second quarter of 2021 on Thursday, August 12, 2021.
-
Acutus Medical, Inc. Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares
7/26/2021
Acutus Medical, Inc. (Nasdaq: AFIB) (“Acutus”) today announced that the underwriter of its previously announced public offering, which closed on July 19, 2021, have exercised in full its option to purchase 825,000 additional shares of common stock from Acutus at the public offering price of $14.00 per share, less underwriting discounts and commissions.
-
Acutus Medical, Inc. Announces Pricing of Public Offering of Common Stock - July 14, 2021
7/14/2021
Acutus Medical, Inc. announced the pricing of its underwritten public offering of 5,500,000 shares of its common stock at a price to the public of $14.00 per share.
-
Acutus Medical, Inc. Announces Proposed Public Offering of Common Stock
7/12/2021
Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB) today announced it has commenced an underwritten public offering of 5,500,000 shares of its common stock.
-
Acutus Medical Reports Preliminary Unaudited Second Quarter 2021 Financial Results
7/12/2021
Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, reported preliminary unaudited results for the second quarter of 2021.
-
Acutus Medical Receives FDA Approval to Initiate US Atrial Fibrillation IDE Trial with the AcQBlate® FORCE Sensing Ablation System
5/27/2021
Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced FDA approval for the company to initiate its Atrial Fibrillation (“AF”) Investigational Device Exemption (IDE) clinical trial for the AcQBlate Force Sensing Ablation Catheter and System.
-
Acutus Medical to Present at the 41st Annual William Blair Growth Stock Conference
5/20/2021
Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will participate at the 41 st Annual William Blair Growth Stock Conference on Thursday, June 3, 2021 at 12:20 p.m. Eastern Time.
-
Acutus Medical Reports First Quarter 2021 Financial Results
5/12/2021
Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the first quarter of 2021.
-
Acutus Medical Announces CE Mark Approval for Suite of Next Generation EP Products in EuropeExpanded and Product Portfolio Strengthens Offering in Access and Therapy Guidance
5/12/2021
Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced CE Mark Approval for a broad suite of EP products that includes the AcQCross™ family of universal transseptal crossing devices, the next generation AcQGuide® MAX and VUE large bore delivery sheaths and the next generation AcQMap® mapping catheter
-
Acutus Medical to Announce First Quarter 2021 Financial Results
4/28/2021
Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today it will release its financial results for the first quarter of 2021 on Wednesday, May 12, 2021
-
Acutus Medical to Participate in Upcoming Investor Conferences
4/20/2021
Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will participate at the following upcoming investor conferences: Attend investor meetings at the Truist Securities 7th Annual Life Sciences Summit on Tuesday, May 4, 2021.
-
Acutus Medical Announces FDA Clearance of AcQCross™, a Full Suite of Universal Transseptal Crossing DevicesProduct Family Targets Over 300,000 Annual US Electrophysiology and Structural Heart Procedures
4/13/2021
Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the FDA clearance of the AcQCross™ family of universal transseptal crossing devices.
-
Acutus Medical Initiates First IDE Therapy Trial with the AcQBlate® FORCE Sensing Ablation System
4/5/2021
Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced initial US enrollments in the company’s AcQForce™ Flutter Investigational Device Exemption (IDE) clinical trial.
-
Acutus Medical to Present at the 20ᵗʰ Annual Needham Virtual Healthcare Conference
3/30/2021
Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that its management team will present at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 3:45 p.m. Eastern Time.
-
Acutus Medical Reports Fourth Quarter and Full Year 2020 Financial Results
3/18/2021
Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, reported results for the fourth quarter and full year ended December 31, 2020.
-
Acutus Medical Board Appoints John Sheridan as a New DirectorNew Board Appointment Brings Demonstrated Leadership in the Medical Device Industry
3/18/2021
Acutus Medical announced the appointment of John Sheridan to the Company's Board of Directors effective March 17, 2021.
-
Acutus Medical Announces Earnings Call Time Change; Fourth Quarter 2020 Earnings Call to Occur at 8 a.m. (Eastern Time)
3/18/2021
Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced that it has changed the timing of its previously announced earnings conference call.